The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to make its selections.
The organization will announce final winers in the competition at ceremony in New York City on October 28, 2021.
In terms of pharmaceutical agents, the organization selected the following 34 nominees:
Company Drug nameAbbVie Inc.
Rinvoq (upadacitinib)
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma
Adhansia XR (methylp…